Invasive Ductal Carcinoma (IDC) Therapeutics Market - By Drug Type, By Type, By End Use - Global Forecast 2025 - 2034

Invasive Ductal Carcinoma Therapeutics Market Size

The global invasive ductal carcinoma (IDC) therapeutics market was valued at USD 9.2 billion in 2024. The market size is estimated to grow from USD 9.9 billion in 2025 to USD 20.6 billion in 2034, growing at a CAGR of 8.5% from 2025 to 2034. One of the major factors driving the growth of this market is the increasing prevalence of breast cancer.
 

As per the National Breast Cancer Foundation, IDC is the most common type of breast cancer, accounting for approximately 80% of the diagnosed breast cancer cases. Furthermore, this foundation states that in 2024 the estimated number of women and men diagnosed with invasive breast cancer in the U.S. were 310,720 and 2,800 respectively. Thus, these significant figures drive the demand for effective ICD therapeutics, thereby contributing to market growth.
 

Additionally, advancement of therapies such as targeted therapies and hormone therapies have also contributed to the growth of IDC therapeutics market. Traditional therapies such as chemotherapy are still essential, but the novel therapies are gaining traction due to their effectiveness and fewer side effects. Thus, with the increased adoption of these advanced novel therapies the market is expected to grow in the coming years.
 

Furthermore, the market is also influenced by the prognosis and survival rates for IDC patients. For instance, according to American Cancer Society, the 5-year relative survival rate for localized IDC is around 99%, encouraging early diagnosis and demand for timely interventions. Moreover, the increased access to healthcare in developing economies is driving the growth of IDC therapeutics market. The increasing presence of pharmaceutical companies and improving healthcare infrastructure in these nations are also increasing the availability of advanced treatments like oral targeted therapies, immunotherapies, and biologics, thus boosting the market growth.
 

Invasive ductal carcinoma therapeutics includes the therapeutics used to manage IDC, which is the most common form of breast cancer. The breast cancer therapeutics including hormone therapies, targeted therapies, chemotherapy and immunotherapy are primarily used for IDC treatment.
 

Invasive Ductal Carcinoma Therapeutics Market Trends

• The market is experiencing significant growth due to rising cases of breast cancer globally and advancements in therapies.
   
• According to the Breast Cancer Research Foundation, in 2022, 1.84 million new cases of IDC were diagnosed, making IDC the most widespread type of breast cancer. This increasing prevalence is driving the demand for IDC therapeutics market.
   
• Further, several initiatives by government and non-government bodies to encourage early diagnosis of breast cancer is fueling the market growth. For example, the Global Breast Cancer Initiative (GBCI) in 2021 was launched by the World Health Organization (WHO), with a goal of lowering death rates from breast cancer by 2.5% annually by 2040 and potentially save 2.5 million lives. The campaign is based on early detection of the disease and effective and complete treatment, aligning with current oncology bioinformatics advancements that enable personalized treatment approaches. Such initiatives help in early diagnosis and increase the adoption rates of effective therapies, thus positively enhance the market growth.
   
• Moreover, development of targeted therapies, such as HER2 inhibitors (trastuzumab, pertuzumab), CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), and PARP inhibitors (olaparib), are advancing IDC treatment since they enhance efficacy and reduce chemotherapy-related toxicity. Immunotherapy and biomarker-driven approaches are developing, especially for triple-negative breast cancer (TNBC), a more aggressive IDC subtype.
   
• Further, every October is observed as the Breast Cancer Awareness Month (BCAM), which has crucial role in rising the awareness among public, screening participation, and fundraising for research. It also campaigns for regular screenings among women above 40 years old, which dramatically increases the chances of successful diagnosis and treatment of IDC, thereby fostering the market growth.
   

Invasive Ductal Carcinoma Therapeutics Market Analysis

• The increase in this segment is driven primarily by the rising prevalence of IDC and advanced cancer diagnostics leading to early diagnosis as the targeted treatment results in increased adoption of the treatment of early-stage IDC with HER2 positive or HR+ IDC.
   
• Another factor driving the growth is the heightened use and acceptance of precision medicine and personalized treatments. HER2 blockades (trastuzumab, pertuzumab, ado-trastuzumab emtansine), CDK4/6 blockers (palbociclib, ribociclib, abemaciclib), and PARP blockaders (olaparib) have revolutionized the practice of treating IDC because they attack the cancer growth mediating pathways.
   
• Additionally, there is an increasing shift towards targeted therapies over chemotherapy which is positively influencing the IDC therapeutics market. The traditional cytotoxic chemotherapy causes certain side effects and consequently low patient compliance. On the other hand, targeted therapies improve the treatment outcomes, making them the preferred first-line treatment option for IDC patients.

• According to Breast Cancer Research Foundation, the hormone receptor is a most common type of IDC and if diagnosed early can lead to better outcomes. Thus, the higher number of cases demonstrates the increasing need for IDC therapeutics for treating hormone receptors.
   
• This type of IDC cancer can be effectively managed by hormone therapies such as aromatase inhibitors and selective estrogen receptor degraders (SERDs), thus the availability of effective treatment options further fosters the growth of this segment.
   
• Further, as HR+ breast cancer generally requires long term treatment, thereby leading to sustained market growth.
   
• Moreover, the population of postmenopausal women is growing globally. For instance, as per the Meno Martha, in 2021, age 50 years and above women accounted for 26% of all women and girls worldwide. As the hormone receptor positive breast cancer is more often diagnosed in postmenopausal women, the demand for IDC treatment also increases.
   

Based on end use, the global invasive ductal carcinoma therapeutics market is classified into hospitals, oncology clinics, and other end users. The hospitals segment is expected to reach USD 3.6 billion by 2034.
 

• Hospitals serve as a primary point of diagnosis and treatment for different cancer patients, due to the advanced diagnostic tools, care from multidisciplinary teams, and specialized oncology departments they offer.
   
• Due to the complexity of various types of therapies involved in the management of IDC such as chemotherapy, targeted therapy, and even immunotherapy, hospital settings are well equipped to handle such comprehensive treatment regimens. Thus, leading to a higher dependency on hospitals for the treatment, thereby propelling the growth of this segment.
   
• The increased patient preference towards hospital-based care is influenced by the availability of emergency units, constant observation, and the presence of skilled staff which further support the growth of this segment.

• The U.S. holds a majority share of the North America IDC therapeutics market because breast cancer has a high prevalence rate in the country. The American Cancer Society projected that 316,950 new cases of invasive breast cancer and 59,080 cases of ductal carcinoma in situ (DCIS) will be diagnosed in 2025. IDC also has a high prevalence which increases the demand for advanced treatment options.
   
• The robust U.S. healthcare system continues to maintain its dominance in the IDC therapeutics market. The world’s best cancer hospitals, diagnostic and research centers, and oncology hospitals provide early diagnostics and advanced treatment. These facilities are equipped with modern technologies that allow for better patient outcomes and wider accessibility to novel therapies, thereby driving the market growth.
   

Germany invasive ductal carcinoma therapeutics market is anticipated to witness considerable growth in the Europe market over the analysis period.
 

• Breast cancer remains the most prevalent form of cancer affecting women in Germany, with an annual incidence estimate of roughly 74,500 new cases. Therefore, the rising IDC diagnosis rates increase the need for advanced therapeutics as well as early detection programs and personalized treatment methodologies.
   
• Germany has an elderly population, with over 21% of its total population being 65 years or older. Given that age is one of the primary contributing factors for developing breast cancer, it is anticipated that the country will continue to see an increasing trend in IDC cases, thus increasing the market need for IDC therapeutics.
   

India invasive ductal carcinoma therapeutics market is anticipated to witness high growth in Asia Pacific market.
 

• Several healthcare initiatives of the government of India have contributed to growing accessibility of cancer treatment. For instance, the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases & Stroke (NPCDCS), formed in 2010, undertakes screening of all types of breast and oral cancers in 100 districts. Such initiatives aid in early diagnosis and awareness of the disease, consequently contributing to market growth.
   
• Another contributor to the growth of this market is increasing awareness and early detection efforts. Breast Cancer India, an online campaign run by The Pink Initiative, Inc. works towards making women aware of the risk, symptoms, and self-examinations of breast cancer. With greater knowledge comes early diagnosis which raises the treatment level of IDC with drug treatments like targeted anti-HER2 therapy, chemotherapy, hormonal therapies, and immunotherapy.
   

In the Latin America invasive ductal carcinoma therapeutics market, Brazil is experiencing significant growth in coming years.
 

• According to the Brazilian National Cancer Institute it is expected that breast cancer remains the most prevalent cancer among women between 2023 to 2025 as it approximately expects there will be 73,610 new cases. Alarmingly, breast cancer is more common in areas with a high Human Development Index (HDI), highlighting the increasing need for sophisticated treatment options, precise therapies, and comprehensive diagnostic initiatives in those regions. 
   
• Brazil's Sistema Único de Saúde (SUS), the country’s universal healthcare system, reinforces market growth by offering free cancer screening, diagnosing, and treatment services.
   
• There is also increased government spending on oncology care which has improved access to IDC treatment, thus fostering the market growth.
   

In Middle East and Africa, Saudi Arabia invasive ductal carcinoma therapeutics market is poised to witness rapid growth over the analysis period.
 

• The government of Saudi Arabia is focusing on the modernization of healthcare facilities, especially oncology departments, which increases the accessibility of IDC therapeutics due to the substantial infrastructural investments made for comprehensive cancer care. This aligns with Saudi Arabia’s Vision 2030 which aims to develop multiple sectors in the Kingdom, including Healthcare.
   
• Furthermore, according to the Saudi Cancer Registry, breast cancer accounts for nearly 30% of all female cancer cases, and IDC is the most prevalent subtype. This high incidence drives the demand for more effective treatment solutions including targeted hormones, chemotherapy, and immunotherapy in the country.
   

Invasive Ductal Carcinoma Therapeutics Market Share

The invasive ductal carcinoma (IDC) therapeutics market is dominated by different pharmaceutical companies such AstraZeneca, Eli Lilly, Roche, Novartis, and Pfizer. These top 5 players accounted for nearly 42% market share as they are actively expanding their oncology portfolios to strengthen their foothold in the competitive landscape. These market players focus on strategies such as mergers, acquisitions, innovative product development and launches, expansion, and collaboration to generate more revenue and withstand market competition.
 

The IDC therapeutics market is expected to witness continued expansion as there is growing investment by companies towards development of novel treatment solutions including biologics, immunotherapies, and precision medicine. Further, with rapid growth in the healthcare system and research capacities in emerging economies, the global accessibility to cutting-edge IDC treatments is likely to improve, further fueling the competitive landscape.
 

Invasive Ductal Carcinoma Therapeutics Market Companies

Some of the prominent players operating in the invasive ductal carcinoma therapeutics industry include:

• AbbVie
• AstraZeneca
• Bristol-Myers Squibb Company
• Celldex Therapeutics
• Eli Lilly and Company
• F. Hoffmann-La Roche
• Janssen Pharmaceuticals
• Macrogenics
• Merck
• Novartis
• Pfizer
   

Pfizer, in collaboration with Alliance Foundation Trials (AFT), demonstrated in the Phase 3 PATINA trial that IBRANCE (palbociclib) significantly improves progression-free survival (PFS) in HR+/HER2+ metastatic breast cancer (MBC). A leader in CDK4/6 inhibitors and targeted therapies, Pfizer’s focus on precision oncology and breakthrough treatments makes it a key innovator in IDC therapeutics. Furthermore, the company’s strong global partnerships and research collaborations drive innovation and accelerated access to advanced IDC treatments.
 

Roche is a global leader in HER2-targeted therapies, offering Herceptin (trastuzumab), Perjeta (pertuzumab), and Kadcyla (T-DM1) for IDC treatment. The company focuses on biomarker-driven strategies and personalized oncology, ensuring effective treatment regimens. Roche’s strong clinical research and biotechnology advancements make it a dominant force in breast cancer therapeutics.
 

Invasive Ductal Carcinoma Therapeutics Industry News

• In January 2025, Enhertu (trastuzumab deruxtecan) of AstraZeneca and Daiichi Sankyo has been approved by the U.S. Food and Drug Administration (FDA) for treating adult patients with unresectable or metastatic HR-positive, HER2-low, or HER2-ultralow breast cancer in the U.S. This approval helped the companies to strengthen their product portfolio and generate revenue growth.
   
• In January 2025, Kazia Therapeutics Limited announced the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib and immunotherapy in advanced breast cancer patients. This initiative enhanced the company’s research credibility and positioned it as an innovator in combination oncology treatments. 
   
• In September 2024, Novartis announced the U.S. FDA approval for Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for treating HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including node-negative (N0) cases. This approval broadened the company’s treatment indications and boosted its market competitiveness.
   
• In November 2023, the U.S. FDA approved capivasertib (Truqap) of AstraZeneca Pharmaceuticals in combination with fulvestrant, for adult patients with HR+/HER2- locally advanced or metastatic breast cancer. This approval reinforced AstraZeneca’s leadership in breast cancer therapeutics, expanding its presence in the HR+/HER2- treatment segment.
   

The invasive ductal carcinoma therapeutics market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Targeted therapy
  • Abemaciclib
  • Ado-trastuzumab emtansine
  • Everolimus
  • Trastuzumab
  • Ribociclib
  • Palbociclib
  • Pertuzumab
  • Olaparib
  • Other targeted therapies 
• Hormone therapy
  • Selective estrogen receptor modulators (SERMs)
  • Aromatase inhibitors
  • Selective estrogen receptor degraders (SERDs)
  • Chemotherapy
  • Immunotherapy       

Market, By Type

• Hormone receptor
• HER2+
• Triple-negative breast

Market, By End Use

• Hospitals
• Oncology clinics
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE